Asfi Rafiuddin, DO
Neurology · Washington, DCNPI 1801200019
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,148 of the $6,239 with a category attached, or 82.5%. 21 manufacturers reported payments, led by Neuropace, Inc. at 34.4% of the total. Reporting peaked in 2019 at $2,153 and has fallen 74.7% since, to $545 in 2025.
Across 262 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$2K
- SK Life Science, Inc.$1K
- UCB, Inc.$1K
- Neurelis, Inc.$802
- Jazz Pharmaceuticals Inc.$291
- Eisai Inc.$166
- plus $772 from 15 others
Across 2 payments — averaging $16,875 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SK Life Science, Inc.$18K
- Immedica Pharma US, Inc.$16K
What the payments were for
- Travel & lodging$1,08417%
- Food & beverage$5,14883%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 14 | $2,147 |
| SK Life Science, Inc. | 52 | $1,048 |
| UCB, Inc. | 48 | $1,013 |
| Neurelis, Inc. | 69 | $802 |
| Jazz Pharmaceuticals Inc. | 31 | $291 |
| Eisai Inc. | 13 | $166 |
| Greenwich Biosciences, Inc. | 3 | $166 |
| Teva Pharmaceuticals USA, Inc. | 1 | $123 |
| Pfizer | 6 | $107 |
| Aucta Pharmaceuticals, Inc. | 7 | $96 |
| Bristol Myers Squibb | 4 | $60 |
| Livanova USA, Inc. | 3 | $50 |
| Novartis | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 2 | $28 |
| Biomarin Pharmaceutical Inc. | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Otter Pharmaceuticals, LLC | 1 | $14 |
| Aprecia Pharmaceuticals, LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Aquestive Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS System$1,677
- Epidiolex$246
- RNS Neurostimulator Kit$162
- VALTOCO$124
- AUSTEDO$123
- Briviact$108
- XCOPRI$106
How this compares
$6,239 in reported general payments places this provider in the 65th percentile of 113 neurology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 39 | $72,261 |
| EpidiolexCannabidiol (Cbd) | 14 | $70,735 |
| Trokendi XrTopiramate | 12 | $31,422 |
| Clobazam | 24 | $3,160 |
| Lacosamide | 23 | $1,840 |
| Levetiracetam | 20 | $1,024 |
| Phenobarbital | 29 | $525 |
| Zonisamide | 19 | $456 |
| Levetiracetam ErLevetiracetam | 12 | $453 |
| Lamotrigine | 16 | $131 |
| Folic Acid | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact | $1,013 | $72,26139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 113 neurology providers in District of Columbia.
Other neurology in Washington
- Laxman BahrooWashington$3.1M
- Fahd AmjadWashington$2M
- Jessica AilaniWashington$1.2M
- Yasar Torres-YaghiWashington$969K
- Benjamin OsborneWashington$747K
- Fernando PaganWashington$690K
- Faria AmjadWashington$557K
- Brian BarryWashington$359K
- Carrie DoughertyWashington$327K
- Carlo TornatoreWashington$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.